SCHEMBL2394980

SCHEMBL2394980

COc1ccc(Nc2nc(C)c(-c3ccc(Cl)c(S(C)(=O)=O)c3)s2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 8/20 0.49
PIK3CG P48736 8/20 0.49
PIK3C3 Q8NEB9 3/20 0.49
PIK3CA P42336 5/20 0.48
PIK3CB P42338 4/20 0.48
PI4KB Q9UBF8 11/20 0.45
PIK3C2A O00443 1/20 0.44
PIK3C2B O00750 1/20 0.44
PI4KA P42356 1/20 0.44
PRKDC P78527 1/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48786 0.88 PIK3CD (0.54) PIK3CDPIK3CGPIK3C3PIK3CAPIK3CB
SCHEMBL2395728 0.79 MEN1 (0.65) PIK3CDPIK3CGPIK3CAPIK3CBMEN1
SCHEMBL48762 0.75 PIK3CD (0.67) PIK3CDPIK3CGPIK3C3PIK3CAPIK3CB
SCHEMBL48392 0.74 PIK3CG (0.83) PIK3CDPIK3CGPIK3C3PIK3CAPIK3CB
SCHEMBL2395287 0.73 PIK3CG (0.61) PIK3CDPIK3CGPIK3C3PIK3CAPIK3CB
SCHEMBL2400384 0.73 PIK3CG (0.56) PIK3CDPIK3CGPIK3C3PIK3CAPIK3CB
SCHEMBL16490500 0.73 PIK3C2G (0.50) PIK3CDPIK3CGPIK3C3PIK3CAPI4KB
SCHEMBL5322864 0.73 PIK3CD (0.68) PIK3CDPIK3CGPIK3C3PIK3CAPIK3CB
SCHEMBL49041 0.72 PIK3CD (0.66) PIK3CDPIK3CGPIK3C3PIK3CAPIK3CB
SCHEMBL14851909 0.72 PIK3C2G (0.60) PIK3CDPIK3CGPIK3CAPI4KBPI4KA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 PIK3CD 42/4885PIK3CG 49/4885PIK3C3 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.